Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Therapeutics

Background:

• Developing efficient delivery systems for combined cancer therapy is crucial.
• Current methods face challenges in co-delivering nucleic acids and small molecule drugs.

Purpose of the Study:

• To create a lipoproteoplex for simultaneous delivery of small interfering RNA (siRNA) and doxorubicin.
• To evaluate the efficacy of this novel system in breast cancer cells.

Main Methods:

• Engineered a supercharged coiled-coil protein (CSP) with cationic properties and a hydrophobic pore.
• Formulated a lipoproteoplex by combining CSP with Lipofectamine 2000.
• Assessed doxorubicin loading capacity and siRNA transfection efficiency in MCF-7 cells.

Main Results:

• The CSP-based lipoproteoplex demonstrated enhanced doxorubicin loading compared to Lipofectamine 2000 alone.
• Achieved significant GAPDH knockdown (60%) in MCF-7 cells, comparable to Lipofectamine 2000.
• Doxorubicin-loaded lipoproteoplex significantly reduced MCF-7 cell viability.

Conclusions:

• The engineered CSP lipoproteoplex is a promising platform for dual delivery of siRNA and doxorubicin.
• This system offers improved drug loading and effective gene silencing for cancer therapy.
• The combined approach shows potential for enhanced breast cancer treatment efficacy.